This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Quality of Care  • Evidence-Based Medicine  • Rheumatology  • Statistics and Research Methods  • Randomized Controlled Trial  • Rheumatoid Arthritis  • Drug Therapy  • Adverse Effects  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Costenbader and colleagues add recently published evidence to our analysis of rare events in patients with RA treated with anti-TNF agents. Two eligible trials^1-2 have been published in full since the end date of our literature search (December 2005), of which only the PREMIER trial results were included in their update. While we have not had the opportunity to fully examine the PREMIER data set with respect to time of occurrence of malignancies, we updated our meta-analysis including new data from both trials (Table). The results are consistent with the findings in our article. Applying Mantel-Haenszel methods incorporating these additional data, the pooled OR for malignancy in patients with RA using anti-TNF antibodies vs placebo remains significantly elevated at 2.4 (95% CI, 1.2-4.8); the OR for serious infections also remains significant at 1.8 (95% CI, 1.2-2.6). These ORs are based on the assessment of the . . . [Full Text of this Article]

Tim Bongartz, MD
bongartz.tim@mayo.edu

Eric L. Matteson, MD, MPH; Victor M. Montori, MD, MSc
Department of Medicine
Mayo Clinic College of Medicine
Rochester, Minn

Alex J. Sutton, PhD
Department of Health Sciences
University of Leicester
Leicester, England

Michael Sweeting, MSc
MRC Biostatistics Unit
Institute of Public Health
Cambridge, England

Iain Buchan, MD, MFPH
Northwest Institute for Bio-Health Informatics
University of Manchester
Manchester, England

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis
Karen H. Costenbader, Roberta Glass, Jing Cui, and Nancy Shadick
JAMA. 2006;296(18):2201.
EXTRACT | FULL TEXT  

Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis
Sarah K. Okada and Jeffrey N. Siegel
JAMA. 2006;296(18):2201-2202.
EXTRACT | FULL TEXT  

Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis
Peter E. Callegari, Thomas F. Schaible, and Jerome A. Boscia
JAMA. 2006;296(18):2202.
EXTRACT | FULL TEXT  

Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis
David Hochman and Bruce Wolff
JAMA. 2006;296(18):2203.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials
Tim Bongartz, Alex J. Sutton, Michael J. Sweeting, Iain Buchan, Eric L. Matteson, and Victor Montori
JAMA. 2006;295(19):2275-2285.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials
Bongartz et al.
Ann Rheum Dis 2009;68:1177-1183.
ABSTRACT | FULL TEXT